Rigel Pharmaceuticals Company Profile (NASDAQ:RIGL)

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company's clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RIGL
  • CUSIP: 76655960
  • Web: www.rigel.com
Capitalization:
  • Market Cap: $319.55 million
  • Outstanding Shares: 122,434,000
Average Prices:
  • 50 Day Moving Avg: $2.60
  • 200 Day Moving Avg: $2.64
  • 52 Week Range: $1.94 - $4.38
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.83
  • P/E Growth: -0.07
Sales & Book Value:
  • Annual Revenue: $18.94 million
  • Price / Sales: 16.87
  • Book Value: $0.69 per share
  • Price / Book: 3.78
Profitability:
  • EBIDTA: ($61,860,000.00)
  • Net Margins: -354.14%
  • Return on Equity: -96.24%
  • Return on Assets: -73.01%
Debt:
  • Current Ratio: 5.77%
  • Quick Ratio: 5.77%
Misc:
  • Average Volume: 951,814 shs.
  • Beta: 1.26
  • Short Ratio: 2.78
 
Frequently Asked Questions for Rigel Pharmaceuticals (NASDAQ:RIGL)

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its earnings results on Tuesday, May, 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.01. The company earned $3.58 million during the quarter, compared to analyst estimates of $4.30 million. Rigel Pharmaceuticals had a negative net margin of 354.14% and a negative return on equity of 96.24%. During the same period in the previous year, the firm posted ($0.19) EPS. View Rigel Pharmaceuticals' Earnings History.

When will Rigel Pharmaceuticals make its next earnings announcement?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Rigel Pharmaceuticals.

Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Rigel Pharmaceuticals' shares. Their forecasts range from $5.00 to $11.00. On average, they expect Rigel Pharmaceuticals' share price to reach $6.40 in the next twelve months. View Analyst Ratings for Rigel Pharmaceuticals.

What are analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (5/10/2017)
  • 2. Jefferies Group LLC analysts commented, "RIGL is on track to submit an NDA for fosta in ITP in 1Q17; next major catalyst could be FDA acceptance by ~May given mixed Ph3 data & limited FDA interactions following Ph3 data. YE16 cash of ~$75M, plus net proceeds of $43M from recent offering, should be sufficient at least for next 12 months including pre-commercial activities, per RIGL. If fosta is approved in ITP, we see >50% upside to our current PT of $5." (3/8/2017)
  • 3. BMO Capital Markets analysts commented, "We remain focused on fostamatinib's pending NDA submission, which we believe supports approval given clear and consistent benefit in ITP, despite one pivotal trial missing statistical significance. We believe reaching an FDA Adcom would be a positive event, as a panel of clinicians would likely recommend approval. Additionally, we believe the fostamatinib addressable patient population is larger than the 18% stable response rate, as real world use would include patients who maintain platelet counts greater than 30K/ul, according to physician feedback. We rate RIGL shares Outperform." (3/8/2017)

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:

  • Raul R Rodriguez, President, Chief Executive Officer, Director
  • Ryan D. Maynard, Chief Financial Officer and Executive Vice President
  • Dolly A. Vance, Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
  • Eldon C. Mayer III, Executive Vice President, Chief Commercial Officer
  • Anne-Marie Duliege M.D., Chief Marketing Officer
  • Keith A. Katkin, Director
  • Bradford S. Goodwin, Independent Director
  • Gary A. Lyons, Independent Director
  • Walter H. Moos Ph.D., Independent Director
  • Peter S. Ringrose Ph.D., Independent Director

How do I buy Rigel Pharmaceuticals stock?

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $2.61.


MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Rigel Pharmaceuticals (NASDAQ:RIGL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.40 (145.21% upside)

Analysts' Ratings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/19/2017BMO Capital MarketsReiterated RatingOutperform -> Outperform$4.00 -> $5.00LowView Rating Details
5/3/2017HC WainwrightReiterated RatingBuy$6.00MediumView Rating Details
3/8/2017Jefferies Group LLCReiterated RatingBuy$5.00HighView Rating Details
11/2/2016Piper Jaffray CompaniesSet Price TargetBuy$11.00N/AView Rating Details
8/3/2016J P Morgan Chase & CoReiterated RatingBuy$5.00N/AView Rating Details
4/23/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Earnings History by Quarter for Rigel Pharmaceuticals (NASDAQ RIGL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017        
5/2/2017Q1 2017($0.12)($0.13)$4.30 million$3.58 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.17)($0.16)$4.25 million$3.00 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)$1.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rigel Pharmaceuticals (NASDAQ:RIGL)
2017 EPS Consensus Estimate: ($0.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Ownership Percentage: 5.21%
Institutional Ownership Percentage: 89.91%
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Anne-Marie DuliegeInsiderSell5,000$2.69$13,450.00View SEC Filing  
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Rigel Pharmaceuticals (NASDAQ:RIGL)
Latest Headlines for Rigel Pharmaceuticals (NASDAQ:RIGL)
Source:
DateHeadline
americanbankingnews.com logoFinancial Contrast: Rigel Pharmaceuticals (RIGL) and Ocata Therapeutics (OCAT)
www.americanbankingnews.com - July 23 at 12:14 PM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 8:00 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 14 at 3:19 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : July 11, 2017
finance.yahoo.com - July 11 at 4:18 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Insider Anne-Marie Duliege Sells 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - July 2 at 7:32 AM
americanbankingnews.com logo Analysts Anticipate Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - July 1 at 12:12 AM
streetinsider.com logoRigel Pharma (RIGL) to Present Data on TAVALISSE (fostamatinib disodium) Phase 3 at EHA Conference on 6/24 - StreetInsider.com
www.streetinsider.com - June 23 at 9:37 AM
finance.yahoo.com logoRigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
finance.yahoo.com - June 23 at 9:37 AM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RIGL) : June 22, 2017
finance.yahoo.com - June 23 at 9:37 AM
zacks.com logoRigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
www.zacks.com - June 22 at 10:47 AM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : June 20, 2017
finance.yahoo.com - June 22 at 10:47 AM
fool.com logoHere's Why Rigel Pharmaceuticals Inc. Is Shining Extra Bright Today - Motley Fool
www.fool.com - June 21 at 4:17 AM
finance.yahoo.com logoRigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
finance.yahoo.com - June 21 at 4:17 AM
streetinsider.com logoPre-Open Movers 06/19: (CLVS) (RICE) (RIGL) Higher; (SGEN) (TSRO) (EQT) Lower (more...)
www.streetinsider.com - June 20 at 2:31 AM
finance.yahoo.com logoRigel Pharma Rises Following FDA Approval
finance.yahoo.com - June 20 at 2:31 AM
finance.yahoo.com logoHere's Why Rigel Pharmaceuticals Inc. Is Shining Extra Bright Today
finance.yahoo.com - June 20 at 2:31 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Receives Outperform Rating from BMO Capital Markets
www.americanbankingnews.com - June 19 at 7:36 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 19 at 2:48 PM
nasdaq.com logoRigel Pharma: FDA To Review NDA For TAVALISSE - Quick Facts
www.nasdaq.com - June 19 at 10:02 AM
finance.yahoo.com logoFDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP
finance.yahoo.com - June 19 at 10:02 AM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 8:37 PM
finance.yahoo.com logoImplied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
finance.yahoo.com - June 16 at 9:20 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Short Interest Down 1.3% in May
www.americanbankingnews.com - June 11 at 8:30 AM
americanbankingnews.com logo$3.00 Million in Sales Expected for Rigel Pharmaceuticals, Inc. (RIGL) This Quarter
www.americanbankingnews.com - June 8 at 9:32 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - June 6 at 10:30 PM
prnewswire.com logoRigel to Present at Jefferies 2017 Global Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - June 1 at 8:30 AM
finance.yahoo.com logoRigel to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 8:30 AM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : May 31, 2017
finance.yahoo.com - May 31 at 12:48 PM
seekingalpha.com logoRigel Pharma: Tavalisse NDA Will Be A Game-Changer - Seeking Alpha
seekingalpha.com - May 26 at 6:31 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 23 at 12:30 PM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 7:24 PM
fool.com logo3 Biotech Stocks I'd Buy Right Now
www.fool.com - May 15 at 6:46 PM
americanbankingnews.com logo Analysts Expect Rigel Pharmaceuticals, Inc. (RIGL) Will Post Quarterly Sales of $3 Million
www.americanbankingnews.com - May 13 at 9:40 AM
americanbankingnews.com logoZacks: Analysts Expect Rigel Pharmaceuticals, Inc. (RIGL) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - May 11 at 8:22 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 7:24 AM
finance.yahoo.com logoETFs with exposure to Rigel Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 7:48 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) to Post FY2017 Earnings of ($0.58) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 5 at 1:22 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. to Post FY2021 Earnings of $0.13 Per Share, Jefferies Group Forecasts (RIGL)
www.americanbankingnews.com - May 4 at 8:38 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 7:46 PM
rttnews.com logoEARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q1 Earnings Report
www.rttnews.com - May 4 at 8:49 AM
seekingalpha.com logoRigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 3 at 7:25 PM
finance.yahoo.com logoEdited Transcript of RIGL earnings conference call or presentation 2-May-17 9:00pm GMT
finance.yahoo.com - May 3 at 7:25 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : May 3, 2017
finance.yahoo.com - May 3 at 7:25 PM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 3 at 5:36 PM
americanbankingnews.com logoRigel Pharmaceuticals (RIGL) Earns Daily Media Impact Score of 0.28
www.americanbankingnews.com - May 3 at 1:03 AM
marketbeat.com logoRigel reports 1Q loss
marketbeat.com - May 2 at 6:38 PM
finance.yahoo.com logoRigel Announces First Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - May 2 at 5:22 PM
finance.yahoo.com logoInvestor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 9:48 AM
americanbankingnews.com logoRigel Pharmaceuticals, Inc. (RIGL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 2 at 7:30 AM

Social

Chart

Rigel Pharmaceuticals (RIGL) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff